Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated abiraterone or enzalutamide.

Methods

This retrospective analysis of the Medicare database (2009-2020) included adult men with ≥1 claim for prostate cancer, metastatic diagnosis, and no prior chemotherapy or novel hormone therapy who initiated first-line (1L) abiraterone or enzalutamide in the index period (September 10, 2014 to May 31, 2017). Cox proportional-hazards models with inverse probability treatment-weighting (IPTW) were used to compare OS between abiraterone- and enzalutamide-trea

SUBMITTER: George DJ 

PROVIDER: S-EPMC11543594 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature